Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 4/20 | 0.57 |
| ▸ | PRKACB | P22694 | 1/20 | 0.57 |
| ▸ | GHSR | Q92847 | 2/20 | 0.54 |
| ▸ | MC4R | P32245 | 2/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511074 | 0.94 | GHSR (0.59) | GHSR | |
| SCHEMBL30029017 | 0.94 | GHSR (0.59) | GHSR | |
| SCHEMBL29419491 | 0.94 | NPBWR1 (0.58) | NPBWR1GHSRIL23R | |
| SCHEMBL29832285 | 0.94 | NPBWR1 (0.58) | NPBWR1GHSRIL23R | |
| SCHEMBL29511125 | 0.94 | PRKACB (0.57) | NPBWR1PRKACBGHSR | |
| SCHEMBL31661149 | 0.94 | GHSR (0.61) | GHSR | |
| SCHEMBL29511045 | 0.93 | MC4R (0.57) | NPBWR1PRKACBGHSRMC4RIL23R | |
| SCHEMBL29511059 | 0.92 | MC4R (0.54) | NPBWR1PRKACBMC4RIL23R | |
| SCHEMBL30919239 | 0.92 | GHSR (0.61) | NPBWR1GHSR | |
| SCHEMBL30878117 | 0.92 | GHSR (0.56) | GHSRMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | NPBWR1 45/4885PRKACB 1401/4885GHSR 33/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | NPBWR1 51/4885PRKACB 2607/4885GHSR 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.